A review article by Prof. Stefan Broer, Ph.D., highlights opportunities and challenges in using amino acid transporters as drug targets. Amino Acid Transporters as Disease Modifiers and Drug Targets provides an overview of methods used to identify new inhibitors for amino acid transporters and outlines cell and organ function where these can be used to modulate, prevent or to treat diseases.
A perspective article in the March 2018 issue of SLAS Discovery from the biology group at the European Screening Centre Newhouse details how the European Lead Factory (ELF), a large publicly accessible drug discovery platform, uses microscale thermophoresis (MST) to aid in the prioritization of small molecule hits from high-throughput screening.
SLAS Discovery (formerly the Journal of Biomolecular Screening) and SLAS Technology (formerly the Journal of Laboratory Automation), both published by SLAS (Society of Laboratory Automation and Screening) in partnership with SAGE Publishing, hosted a special reception to celebrate the 2018 SLAS Journal Achievement Award honorees on Feb. 6 at SLAS2018, the SLAS International Conference and Exhibition, held Feb. 3-7, 2018, in San Diego, CA.
Three organizations earned a SLAS New Product Award yesterday at SLAS2018 in San Diego for their innovative new productsthat have played an important role in the advancement of life sciences drug discovery and development.
SLAS2018 was all about science and innovation as new keynote lectures, cutting-edge podium presentations and the new SLAS Ignite Theater series stoked the collaborative nature of today's life sciences professionals with three days of ground-breaking presentations that left attendees pondering new ways to keep pace with the speed of science.
A phenotypic high-throughput screen to identify modulators that improve mutant cystic fibrosis transmembrane conductance regulator (CFTR) activity is described in the SLAS Discovery February 2018 front cover feature article by Giuliano and colleagues of Proteostasis Therapeutics, Inc. (Cambridge, MA).
“The 2018 SLAS Technology Ten represent some of the most innovative scientific achievements that were featured in SLAS Technology in the past 12 months,” says Editor-in-Chief Edward Kai-Hua Chow, PhD (National University of Singapore).
Life sciences professionals and business development dealmakers from all walks of industry, academia and government have a new interchange at SLAS2018 – SLAS Ignite, a series of programs that foster scientific innovation through collaboration, debuts at the 2018 SLAS International Conference and Exhibition (SLAS2018), Feb. 3-7, in San Diego, CA.
A new article in the February 2018 issue of SLAS Technology describes a new platform that could change the way cancer is diagnosed and treated by automating the isolation of circulating tumor cells (CTCs) directly from cancer patient blood. This article provides unique insight into the development of a commercial system that has the potential to change the standard of care in cancer diagnosis and treatment.
A new original research article in SLAS Discovery presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5’-Nucleotidase, a promising target for developing anti-cancer drugs.
This new (and freely available) original research article presents a fast, robust and accurate methodology for correlating compound identity to CYP1A2 potency of inhibitors in metabolic mixtures. The methodology is centered around an at-line nanofractionation platform in which a metabolic mixture is chromatographically separated followed by parallel on-line mass spectrometric (MS) analysis and at-line nanofractionation on high-density microtiter well plates that are then directly exposed to a bioassay.
An original research report by Eun Jeong Cho et al. (University of Texas at Austin) in the January 2018 Issue of SLAS Discovery presents a newly designed biochemical assay that is rapid, sensitive, inexpensive, and high-throughput screening (HTS)-friendly to identify antagonist against aldolase A (ALDOA).
A new methodology enables the investigation of a large number of structurally conserved enzymes belonging to the Fe(II)/2-oxoglutarate-dependent dioxygenase superfamily.
SLAS Discovery marks the 30th anniversary of Matrix Assisted Laser Desorption/Ionization Time of Flight (MALDI TOF), the soft ionization technique for analyzing non-volatile biomolecules using mass spectrometry, with a special issue showcasing 10 new research reports.
A review article in the December 2017 issue of SLAS Technology provides important information for life sciences and technology professionals in academia and industry and members of the general public who are interested in antibiotic resistance, general microbial detection principles, in vitro diagnostics, micro- and nanotechnologies, and next generation rapid microbial testing methods.
A new SLAS Technology review article by researchers at the University of Southern California and the University of California, Los Angeles, sheds light on the growing number and more sophisticated designs of theranostic nanoparticles.
SLAS is pleased to announce the addition of Emilio Diez Monedero, Peter Brian Simpson and Severine Tamas-Lhoustau to the Society's Board of Directors. They begin three-year terms in February 2018.
A new SLAS Discovery article available for free ahead-of-print enables researchers to derive more clinically-relevant information from 3D cell culture models.
Discovering new drugs has never been easy and some potential drug targets have historically been viewed as too challenging and thus off limits for prosecution. In a new SLAS Discovery review, authors John S. Lazo et al. of the University of Virginia reflect on the nature of protein tyrosine phosphatases and explores reasons why these enzymes have been eschewed by drug hunters, and how the landscape is beginning to change.
A new report shows how microsystems can be used to understand processes in heart tissue in detail and to test newly developed compounds applied in the treatment of cardiac diseases.
An exploration of the latest understanding of the complex mechanisms behind OA pain offers new possibilities and potential treatment targets for osteoarthritis (OA) pain. New areas of research discussed include the use of combination therapies and the development of biomarkers to target effective pain treatment.
The August 2017 issue of SLAS Technology (formerly the Journal of Laboratory Automation) showcases 10 new reviews and original research reports that illustrate how the progression of research assays from qualitative outputs toward increasingly sensitive quantitative outputs is transforming life sciences and biomedical research and diagnostics by improving the ability of researchers and clinicians to detect and quantify increasingly complex assays.
Information generated by screening tools, readily available therapies and potential pathways to drug development are the cornerstone of informed clinical research and clinical trial design. In a new review in the August 2017 issue of SLAS Discovery (formerly the Journal of Biomolecular Screening), authors Eric Chevet, Ph.D., of Inserm U1242 (Rennes, France) et al. analyze the recent literature and review the impact of unfolded protein response (UPR) in health and disease.
Jill Hronek, Director of Marketing Communications
Telephone: +1.630.256.7527, ext. 103